SCHEMBL2102873

SCHEMBL2102873

C=C1C(=O)O[C@H]2C[C@@H](C)[C@@H]3CC(=O)OC[C@@]3(C)C[C@H]12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 2/20 0.51
▸ MAPT P10636 4/20 0.49
▸ RAB9A P51151 4/20 0.49
▸ NPC1 O15118 3/20 0.49
▸ XBP1 P17861 3/20 0.49
▸ HTT P42858 3/20 0.49
▸ MDM2 Q00987 3/20 0.49
▸ PKM P14618 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ TDP1 Q9NUW8 2/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ STAT3 P40763 1/20 0.40
▸ NLRP3 Q96P20 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ TERT O14746 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29359310 1.00 PTGS2 (0.51) PTGS2MAPTRAB9ANPC1XBP1
SCHEMBL30402377 0.72 MAPT (0.55) PTGS2MAPTRAB9ANPC1XBP1
SCHEMBL31626700 0.72 PTGS2 (0.59) PTGS2MAPTRAB9ANPC1XBP1
Confertin SCHEMBL30139341 0.72 PTGS2 (0.59) PTGS2MAPTRAB9ANPC1XBP1
Graveolide SCHEMBL31279270 0.72 PTGS2 (0.59) PTGS2MAPTRAB9ANPC1XBP1
SCHEMBL28044817 0.72 PTGS2 (0.59) PTGS2MAPTRAB9ANPC1XBP1
Pseudoguaianolide SCHEMBL31387995 0.71 PTGS2 (0.55) PTGS2MAPTRAB9ANPC1XBP1
SCHEMBL6424628 0.69 PTGS2 (0.53) PTGS2MAPTRAB9ANPC1XBP1
Burrodin SCHEMBL30072218 0.68 PTGS2 (1.00) PTGS2MAPTRAB9ANPC1XBP1
SCHEMBL31237447 0.68 PTGS2 (0.57) PTGS2MAPTRAB9ANPC1XBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069216-A1 MULTIPLE PARTIALLY REDUNDANT BIOMETRIC SENSING DEVICES POLTORAK TECH LLC (US) 2026-03-12 — — US disclosed
US-20260029410-A1 PROGNOSTIC AND DIAGNOSTIC METHODS FOR RISK OF ACUTE KIDNEY INJURY PREVENCIO INC (US) 2026-01-29 — — US disclosed
US-12465292-B2 Multiple partially redundant biometric sensing devices POLTORAK TECHNOLOGIES LLC (US) 2025-11-11 — — US disclosed
EP-4626417-A1 METHODS AND COMPOSITIONS FOR IMPROVING DRIVING PERFORMANCE AXSOME THERAPEUTICS (US) 2025-10-08 — — EP disclosed
US-20250229484-A1 SYSTEMS, METHODS, AND COMPOSITIONS FOR ADDITIVE MANUFACTURING 3D SYSTEMS INC (US) 2025-07-17 — — US disclosed
US-11958798-B2 Process for the preparation of iloprost EUROAPI HUNGARY LIMITED LIABILITY COMPANY (HU) 2024-04-16 — — US disclosed
CN-112218847-B Method for preparing iloprost 奇诺因药物和化学工厂私人有限公司 2024-03-08 — — CN disclosed
EP-4296256-A2 PROCESS FOR THE PREPARATION OF ILOPROST EUROAPI Hungary Limited Liability Company (HU) 2023-12-27 — — EP disclosed
EP-3781544-B1 PROCESS FOR THE PREPARATION OF ILOPROST EUROAPI HUNGARY LLC (HU) 2023-11-08 — — EP disclosed
US-20230115500-A1 PROCESS FOR THE PREPARATION OF ILOPROST CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) 2023-04-13 — — US disclosed
US-11450744-B2 Transition-metal oxides-coated hydrogen-terminated diamond surface and uses thereof TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2022-09-20 — — US disclosed
US-20220178946-A1 PROGNOSTIC AND DIAGNOSTIC METHODS FOR RISK OF ACUTE KIDNEY INJURY PREVENCIO, INC. 2022-06-09 — — US disclosed
US-20220160309-A1 MULTIPLE PARTIALLY REDUNDANT BIOMETRIC SENSING DEVICES POLTORAK TECHNOLOGIES LLC 2022-05-26 — — US disclosed
CN-109196111-B Process for producing optically active carboxylic acids, carboxylic acid salts and carboxylic acid derivatives containing triple bonds 奇诺因药物和化学工厂私人有限公司 2022-03-11 — — CN disclosed
US-8165022-B2 Transmitting/receiving method and program and recording medium SHARP KABUSHIKI KAISHA (JP) 2012-04-24 — — US disclosed
US-20090279451-A1 TRANSMITTING/RECEIVING METHOD AND PROGRAM AND RECORDING MEDIUM SHARP KABUSHIKI KAISHA (JP) 2009-11-12 — — US disclosed
US-6485400-B1 Gymnastic means SERLACHIUS JARL-FREDRIK (FI) 2002-11-26 — — US disclosed
EP-0797467-B1 GYMNASTIC MEANS SERLACHIUS JARL FREDRIK (FI) 2001-10-24 — — EP disclosed
EP-0797467-A1 GYMNASTIC MEANS Serlachius, Jarl Fredrik (FI) 1997-10-01 — — EP disclosed
WO-1995021664-A1 GYMNASTIC MEANS SERLACHIUS JARL FREDRIK (FI) 1995-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260029410-A1 PROGNOSTIC AND DIAGNOSTIC METHODS FOR RISK OF ACUTE KIDNEY INJURY KLKB1, SERPINA6, FABP3 PTGS2 2582/4885MAPT 4505/4885RAB9A 1607/4885
US-20230115500-A1 PROCESS FOR THE PREPARATION OF ILOPROST PTGIS, PTGER1, PTGIR PTGS2 13/4885MAPT 4667/4885RAB9A 2847/4885
US-11958798-B2 Process for the preparation of iloprost PTGIS, PTGER1, PTGIR PTGS2 13/4885MAPT 4667/4885RAB9A 2847/4885
US-20260069216-A1 MULTIPLE PARTIALLY REDUNDANT BIOMETRIC SENSING DEVICES VEGFA, KDR, TGFBR1 PTGS2 258/4885MAPT 2029/4885RAB9A 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback